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Background: Atrial ﬁbrillation (AF) is a common arrhythmia in patients with heart failure (HF); however,
its impact on unselected outpatients with HF remains unclear.
Methods: We followed 2024 symptomatic outpatients with HF who visited the Cardiovascular Institute
Hospital (The Shinken Database: 2004–2011, N¼17,517). We examined the prevalence, clinical char-
acteristics, and outcomes of AF in these outpatients with HF.
Results: AF was observed in 310 of the patients (15%). Patients with AF were older; more likely to be
female; and had lower rates of hypertension, diabetes mellitus, and ischemic heart disease. However,
they also had higher rates of New York Heart Association grades III/IV, lower left ventricular ejection
fraction (EF), renal dysfunction, and dilated cardiomyopathy. The use of cardiovascular drugs including
beta-blockers, renin-angiotensin-system inhibitors, diuretics, digitalis, and antiarrhythmic drugs was
more common in patients with AF. Kaplan–Meier curves revealed that the incidences of all-cause death,
cardiovascular disease death, and HF-related admission were signiﬁcantly higher in patients with AF.
Kaplan–Meier curves and an unadjusted Cox regression analysis showed that AF was associated with a
signiﬁcantly higher risk of all-cause death, cardiovascular death, and HF-related admission. However, the
adjusted Cox regression model showed that AF was no longer an independent risk factor for all-cause
death, cardiovascular death, and HF death but remained an independent risk factor of HF-related
admission (hazard ratio, 1.781; 95% conﬁdence interval, 1.172–2.704; p¼0.007).
Conclusions: AF was frequently observed in outpatients with HF. AF was not associated with long-term
mortality but was independently associated with HF-related admission in this outpatient population.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Atrial ﬁbrillation (AF) is one of the most common arrhythmia types
in patients with heart failure (HF) [1–4]. Although AF was historically
thought to deteriorate HF by various mechanisms including loss of
atrial contraction, tachycardia, and irregular ventricular ﬁlling time,
recent studies have demonstrated that the presence of AF was not
associated with long-term mortality in patients with HF [4–6].
However, the enrolled patients in these studies were com-
monly those with severe HF and reduced left ventricular function
requiring hospitalization. Hence, the impact of AF on unselected
outpatients with HF remains unclear. Moreover, the prognostic
signiﬁcance of preexisting AF and later development of AF in
patients with HF was thought to differ. The Framingham study
showed that preexisting AF was not associated with adverse
survival in patients with HF [7]. However, the prognostic signiﬁ-
cance of AF coexisting with HF in outpatients in Japanese clinical
practice is not fully understood. Therefore, in the present study,
we aimed to clarify the impact of AF on long-term clinical
outcomes in unselected outpatients with HF by using a hospital-
based cohort from The Shinken Database [8].
2. Material and methods
2.1. Study population and protocol
The Shinken Database comprises all new patients (inpatients
and outpatients) visiting the Cardiovascular Institute in Tokyo,
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Japan (“Shinken” is a Japanese abbreviation of the hospital name),
excluding patients with active cancer and any foreign travelers.
The principal aim of this hospital-based database is to survey the
prevalence and prognosis of cardiovascular diseases in urban areas
of Japan [9–13]. The registry was started in June 2004; thereafter,
patients have been continually registered on an annual basis. The
data in the present study were derived from this database
between June 2004 and March 2012 (Shinken Database 2004–
2011), including 17,517 new visiting patients. Based on the con-
gestion ﬁndings, patients with HF (n¼2024) were deﬁned as those
with symptomatic HF (New York Heart Association [NYHA] classes
II–IV) in this study [8,10]. The patient selection ﬂow chart is shown
in Fig. 1. We tracked the patients an average of 11337782 days
with a follow-up rate of 72.3%.
2.2. Ethics
The ethical committee granted ethical permission for this
study, and all patients gave written informed consent. The study
was performed in accordance with the Declaration of Helsinki.
2.3. Data collection
In each patient, after electrocardiogram (ECG) and chest radio-
graph readings were obtained, cardiovascular status was evaluated
by performing echocardiography, exercise test, 24-h Holter record-
ings, and blood laboratory data according to the attending physi-
cian's decision within 3 months after the ﬁrst visit. In the present
study, AF was diagnosed based on ECG recordings, including
12-lead surface ECG and 24-h Holter recordings performed
3 months after the initial visit as well as by the medical history
of AF from the referring physician. The following data were
collected as the initial clinical parameters: sex, age, body mass
index (BMI), drug information, coexisting conditions including
hypertension, diabetes mellitus (DM), and dyslipidemia. The
following echocardiographic parameters were collected: left ven-
tricular (LV) diameter of diastole (LVDd), LV diameter of systole
(LVDs), interventricular septum thickness (IVST), posterior wall
thickness (PWT), and LV ejection fraction (LVEF).
Anemia was deﬁned as hemoglobin level o11 g/dL [14]. The
estimated glomerular ﬁltration rate (eGFR) was calculated by using
the GFR equation for the Japanese population: GFR¼194 (serum
creatinine)1.094 (age)0.287 (0.739 if female) [15]. Obesity was
deﬁned as a BMIZ25 kg/m2. Chronic kidney disease (CKD) was
deﬁned as a baseline eGFRo60mLmin1 1.73 m2 [16,17]. Ischemic
heart disease (IHD) was considered present if the patient had one of
the following: (1) a documented history of myocardial infarction,
angina, or prior coronary revascularization; (2) pathologic Q waves on
ECG; or (3) 475% stenosis in one or more coronary arteries on
coronary angiograms. Valvular heart disease was deﬁned as valvular
heart disease with moderate or greater severity.
Idiopathic dilated cardiomyopathy (DCM) was diagnosed based
on the presence of global LV dilatation with impaired systolic
function occurring in the absence of known cardiac causes.
Hypertrophic cardiomyopathy was diagnosed by performing echo-
cardiography when hypertrophy (IVST or PWT412 mm) without
hypertension was present. We conﬁrmed the deaths of the study
patients in the medical records of our hospital or from the
obtained follow-up information.
2.4. Patient follow-up
The health status of each patient and the incidence of cardio-
vascular events and mortality are maintained in the database
through a link to the hospital medical records and from study
documents of prognosis sent once per year to patients who
discontinued hospital visits or have been referred to other
hospitals.
In the present data analysis, follow-up data collected after April
1, 2012, were excluded. Therefore, the end of the follow-up period
was deﬁned as one of the following three time points: (1) date of
death before March 31, 2012; (2) ﬁnal hospital visit or the date of
the ﬁnal response to our study documents of prognosis with the
conﬁrmation of being alive before March 31, 2012; or (3) March 31,
2012, when the date of death, ﬁnal hospital visit, or ﬁnal response
to our study documents of prognosis were later than April 1, 2012.
We conﬁrmed HF events (HF requiring hospitalization; death
due to HF) that were classiﬁed into the International Classiﬁcation
of Diseases, 10th revision, code I50, using the hospital's medical
records or patient follow-up. We excluded events that occurred at
the initial visit. “Cardiovascular disease death” included death
resulting from acute myocardial infarction, sudden cardiac death,
HF death, death due to stroke, and death due to other cardiovas-
cular causes.
2.5. Statistical analysis
The categorical and consecutive data of the patients' back-
ground characteristics are presented as number (%) and mean
7standard deviation, respectively. The χ2 test was used for group
comparison, while the unpaired t-test was used to compare
consecutive variables. Long-term event-free survival was esti-
mated by using Kaplan–Meier curves, and the log-rank test was
used to assess the signiﬁcance of differences between the two
groups. Unadjusted and adjusted Cox regression analyses were
performed to identify the effects of AF on long-term clinical
outcomes including all-cause death, cardiovascular disease death,
HF death, and HF-related admission. In the adjusted Cox regres-
sion model, the effect of AF was adjusted for the following
covariates: age; sex; obesity; hypertension; dyslipidemia; DM;
hyperuricacidemia; cigarette smoking; CKD; anemia; IHD; valvular
heart disease; DCM; B-type natriuretic peptide (BNP); NYHA class;
LVEF; and the use of beta-blockers, renin-angiotensin-system
inhibitors (RAS-Is), statins, diuretics, digitalis, antiarrhythmic
drugs (AADs), antiplatelet drugs, or warfarin. In a sub-analysis,
we divided the study patients into two subgroups based on sex,
age (Z65 vs. o65 years), etiology (ischemic vs. non-ischemic,
valvular vs. non-valvular), LVEF (preserved EF [450%] vs. reduced
EF [r50%]), and HF severity (NYHA II vs. NYHA III/IV).
We performed Cox regression analysis to identify the impact of
AF on HF admission in each subgroup. A probability value o0.05
indicated statistical signiﬁcance. These analyses were performed
by using SPSS version 19.0 software (SPSS Inc., Chicago, IL, USA).
Fig. 1. Patient selection ﬂow chart.
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3. Results
3.1. Patient characteristics
Among the 17,517 patients who visited our hospital, 2024
outpatients presented with symptomatic HF. AF was observed in
310 patients (15%). Patients with AF were older; more likely to be
female; more likely to have lower rates of obesity, hypertension,
dyslipidemia, DM, a prior history of percutaneous coronary inter-
vention, and IHD; and had higher rates of hyperuricacidemia, CKD,
valvular heart disease, DCM, and a prior history of stroke. The
average BNP in patients with AF was signiﬁcantly higher than that
in patients without AF.
The AF group had a lower prevalence of NYHA II but had a
higher prevalence of NYHA III and IV HF than the non-AF group
(Table 1). The use of beta-blockers, RAS-Is, diuretics, digitalis,
AADs, and warfarin was more common in patients with AF,
whereas the use of statins and antiplatelet drugs was more
common in patients without AF (Table 2). Ultrasound cardiography
showed that LVDd and LVDs were greater in patients with AF than
in those without AF. Additionally, LVEF was lower in patients with
AF than in those without it (Table 3).
3.2. Clinical outcomes
Overall, all-cause death occurred in 32 patients (3.2%/person/
year) in the AF group and 108 patients (2.0%/person/year) in the
non-AF group. Death due to cardiovascular disease (HF death)
occurred in 19 (six) patients (1.9%/person/year [0.6%/person/year])
in the AF group and 52 (20) patients (0.9%/person/year [0.4%/
person/year]) in the non-AF group. HF admission occurred in 62
patients (7.3%/person/year) in the AF group and in 119 patients
(2.3%/person/year) without AF. The Kaplan–Meier curves revealed
that the rates of all-cause death, cardiovascular disease death, and
HF admission were signiﬁcantly higher in patients with AF than in
those without (Fig. 2).
Similarly, the unadjusted Cox regression analysis showed that
AF was associated with a signiﬁcantly higher risk of all-cause
death (hazard ratio [HR], 1.631; 95% conﬁdence interval [95% CI],
1.099–2.420, p¼0.015), cardiovascular disease death (HR, 2.022;
95% CI, 1.196–3.420; p¼0.009), and HF admission (HR, 3.107; 95%
CI, 2.286–4.224; po0.001). However, the adjusted Cox regression
model showed that AF was no longer an independent risk of all-
cause death (HR, 0.573; 95% CI, 0.286–1.146; p¼0.115), cardiovas-
cular disease death (HR, 0.772; 95% CI, 0.320–1.861; p¼0.564), and
HF death (HR, 0.690; 95% CI, 0.167–2.844; p¼0.608), and but was a
still independent risk of HF admission (HR, 1.781; 95% CI, 1.172–
2.704; p¼0.007) (Table 4).
3.3. Sub-analysis
As a sub-analysis, the HR of AF for HF-related admission in
different subgroups stratiﬁed based on sex, age (Z65 vs. o65
years), etiology (ischemic vs. non-ischemic, valvular vs. non-
valvular), LVEF (preserved EF450% vs. reduced EFr50%), and
HF severity (NYHA II vs. NYHA III/IV) are shown in Table 5. The
clinical impact of AF on HF admission seemed to be stronger in
patients with ischemic etiology compared to those without
ischemic etiology, non-valvular etiology compared to those with
valvular disease, and preserved EF compared to those with
reduced EF (Table 5).
Table 1
Patient characteristics.
AF absent (n¼1714) AF present (n¼310) p Value
Age (years) 63.8712.9 67.8711.9 o0.001
Male sex (%) 73.5 63.2 o0.001
Obesity (%) 35.7 23.3 o0.001
Hypertension (%) 60.0 53.9 0.044
Dyslipidemia (%) 58.4 36.5 o0.001
Diabetes mellitus (%) 30.0 23.9 0.023
Hyperuricacidemia (%) 11.6 17.1 0.007
Cigarette smoking (%) 22.8 10.6 o0.001
CKD (%) 31.0 46.9 o0.001
Anemia (%) 10.0 16.1 0.002
Prior stroke (%) 4.6 7.4 0.033
Prior PCI (%) 12.0 7.7 0.031
Prior CABG (%) 3.7 1.9 0.120
BNP (pg/mL) 3247592 4147639 0.037
Cause of heart failure
IHD (%) 74.8 34.5 o0.001
Valvular disease (%) 24.5 62.3 o0.001
DCM (%) 4.8 10.6 o0.001
HCM (%) 2.7 3.2 0.636
NYHA class
II (%) 80.9 75.5 0.027
III (%) 16.5 21.0 0.052
IV (%) 2.6 3.5 0.362
AF, atrial ﬁbrillation; CKD, chronic kidney disease; PCI, percutaneous coronary
intervention; CABG, coronary artery bypass graft surgery; BNP, B-type natriuretic
peptide; DCM, idiopathic dilated cardiomyopathy; IHD, ischemic heart disease;
HCM, hypertrophic cardiomyopathy; and NYHA, New York Heart Association.
Data are expressed as either mean7standard deviation or percentage.
Table 2
Medications.
AF absent (n¼1714) AF present (n¼310) p Value
Beta-blockers (%) 38.7 51.9 o0.001
Calcium channel blockers (%) 26.8 24.8 0.463
ACE-Is (%) 15.2 21.9 0.003
ARBs (%) 37.6 43.9 0.028
RAS-Is (%) 48.8 58.7 0.001
Statins (%) 48.0 27.1 o0.001
Diuretics (%) 31.3 63.5 o0.001
Digitalis (%) 4.0 33.9 o0.001
AADs (%) 47.3 67.7 o0.001
Antiplatelet drugs (%) 77.8 69.0 0.001
Warfarin (%) 20.7 70.0 o0.001
AAD, antiarrhythmic drug; ACE-I, angiotensin-converting enzyme inhibitor; AF,
atrial ﬁbrillation; ARB, angiotensin II receptor blocker; and RAS-I, renin-angiotensin
system inhibitor.
Data are expressed as percentages.
Table 3
Ultrasound cardiography data.
AF absent (n¼1714) AF present (n¼310) p Value
IVST (mm) 9.872.3 9.572.2 0.019
PWT (mm) 8.971.7 8.871.7 0.106
LVDd (mm) 49.779.0 52.6710.0 o0.001
LVDs (mm) 33.9711.0 37.1712.1 o0.001
LVFS (%) 33.2710.2 30.7711.2 o0.001
LVEF (%) 60.1715.9 56.1717.7 o0.001
AF, atrial ﬁbrillation; IVST, interventricular septum thickness; LVDd, left ventricular
end-diastolic dimension; LVDs, left ventricular end-systolic dimension; LVEF, left
ventricular ejection fraction; LVFS, left ventricular fractional shortening; and PWT,
posterior wall thickness.
Data are expressed as either mean7standard deviation or percentage.
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Fig. 2. Kaplan–Meier curves for (A) all-cause death-free survival rate, (B) cardiovascular disease death-free survival rate, (C) heart failure death-free survival rate, and
(D) heart failure admission-free survival rate. AF, atrial ﬁbrillation.
Table 4
Hazard ratio for clinical outcomes.
HR 95% CI p Value
All-cause death
Unadjusted HR 1.631 1.099–2.420 0.015
Adjusted HR 0.573 0.286–1.146 0.115
Cardiovascular disease death
Unadjusted HR 2.022 1.196–3.420 0.009
Adjusted HR 0.772 0.320–1.861 0.564
HF death
Unadjusted HR 1.655 0.665–4.121 0.279
Adjusted HR 0.690 0.167–2.844 0.608
HF admission
Unadjusted HR 3.107 2.286–4.224 o0.001
Adjusted HR 1.781 1.172–2.704 0.007
Unadjusted and adjusted hazard ratios for clinical outcomes by atrial ﬁbrillation.
HF, heart failure; HR, hazard ratio; and CI, conﬁdence interval.
Table 5
Subgroup analysis of HF-related admission based on AF.
N HR 95% CI p Value
Male 1456 2.895 1.968–4.260 o0.001
Female 568 3.367 2.008–5.647 o0.001
Age Z65 years 1040 2.633 1.790–3.872 o0.001
Age o65 years 984 3.628 2.165–6.077 o0.001
IHD 1389 3.626 2.122–6.197 o0.001
Non-IHD 635 1.704 1.149–2.528 0.008
Valvular disease 613 1.459 0.985–2.162 0.060
Non-valvular disease 1411 4.586 2.755–7.632 o0.001
HFpEF 1,481 3.964 2.595–6.058 o0.001
HFrEF 449 1.813 1.138–2.889 0.012
NYHA II 1,621 3.337 2.273–4.898 o0.001
NYHA III/IV 403 2.400 1.438–4.006 0.001
AF, atrial ﬁbrillation; CI, conﬁdence interval; HF, heart failure; HFpEF, heart failure
with preserved ejection fraction; HFrEF, heart failure with reduced ejection
fraction; HR, hazard ratio; IHD, ischemic heart disease; and NYHA, New York Heart
Association.
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4. Discussion
The present study was performed in an observational cohort of
outpatients with HF, and the results of this study revealed the
impact of AF on Japanese outpatients with HF in real-world clinical
settings. The major ﬁndings of the present study are as follows.
(1) AF was complicated in 15% of outpatients with HF visiting a
cardiovascular hospital in Japan. (2) Patients with AF were older
and more likely to be female. The use of cardiovascular drugs
including beta-blockers, RAS-Is, diuretics, digitalis, and AADs was
more common in patients with AF. LVEF was lower in patients
with AF than in those without. (3) AF was not associated with
higher mortality but was independently associated with a higher
incidence of HF-related admission. (4) The HR of AF for HF-related
admissions tended to be higher in patients with ischemic etiology,
without valvular disease, and with preserved EF.
AF is a common arrhythmia type in patients with HF, and its
prevalence in patients with HF has been reported to be 10–50% [1–4],
varying according to HF severity and the background characteristics
of the study patients. In the present study, AF was seen in 15% of
outpatients with HF visiting a cardiovascular hospital in Japan. This
prevalence is in agreement with those of previous studies that
included outpatients with HF [1,18,19].
In the present study, after adjustment for covariates, out-
patients with HF and AF had a comparable risk of all-cause death
to those without AF. Studies have reported that AF is an indepen-
dent predictor of all-cause mortality in patients with HF [20].
However, because of changes in therapeutic trends, such as the
avoidance of class I AADs and the administration of RAS-Is, the
clinical outcomes of patients with HF and AF have improved
dramatically [21]. Results from the Japanese Cardiac Registry of
Heart Failure in Cardiology (JCARE-CARD) [5], including hospita-
lized patients with HF, also demonstrated that the presence of AF
in HF patients was not associated with higher mortality, a ﬁnding
that was in agreement with those of the present study. However,
although AF was not associated with HF-related readmission after
hospital discharge in JCARE-CARD, it was signiﬁcantly associated
with the long-term incidence of HF admission in our outpatients
with HF even after adjustment for covariates.
The clinical impact of AF on the clinical outcomes in patients
with HF might differ between outpatients and hospitalized
patients. The clinical characteristics of patients with AF and those
without it apparently differ—for example, outpatients with HF and
AF were more likely to be female and older and had a lower
prevalence of IHD, reduced LVEF, and more severe HF symptoms
than those without AF. Hence, we divided the study patients based
on sex, age (Z65 vs. o65 years), etiology (ischemic vs. non-
ischemic, valvular vs. non-valvular), LVEF (preserved EF450% vs.
reduced EFr50%), and HF severity (NYHA II vs. NYHA III/IV).
Subgroup analysis showed that the impact of AF was stronger in
patients with ischemic etiology compared to those without
ischemic etiology, those without valvular disease compared to
those with valvular disease, and those with preserved EF com-
pared to those with reduced EF. In addition, AF was signiﬁcantly
associated with long-term HF admission in patients with HF and
preserved LVEF.
Regarding the pathophysiology of HF with preserved LVEF, AF is
one of the most important precipitating factors related to diastolic
dysfunction [22,23]. AF might have important roles in the patho-
genesis of HF with preserved EF in association with diastolic HF.
Compared with JCARE-CARD, which included patients hospitalized
with severe HF, the patients included in the present study had a
higher prevalence of ischemic etiology and preserved EF. These
differences in etiology and the prognostic signiﬁcance of AF might
contribute to the different results of various studies including
those of our study, JCARE-CARD, and other studies performed in
Western countries focusing on the prognostic value of AF in
patients with HF. Therefore, we need to consider the etiology
and various factors when we speculate the prognostic signiﬁcance
of AF in patients with HF.
The present study has several limitations. In this study, enrolled
patients were divided into AF and non-AF groups according to ECG
recordings, including 12-lead surface ECG and 24-h Holter ECG
recordings performed 3 months after the initial visit; thus,
patients who had a history of asymptomatic AF but were in sinus
rhythm at baseline were categorized into the non-AF group.
Moreover, the present study did not obtain data about new-
onset AF 3 months after the ﬁrst visit, which has been reported
to have a prognostic effect in patients with HF [3,6,7]. As shown in
Section 3, the background characteristics of the study patients
differed between groups. Thus, even after adjustment based on the
covariates, the independent prognostic value of AF in outpatients
with HF was not determined in this study. As such, further studies
are needed. Finally, this study was based on a single-center cohort;
thus, its results cannot be extended to the general population.
In conclusion, the present study of an observational cohort of
unselected outpatients with HF revealed that AF is a common
arrhythmia type in HF. Preexisting AF was not associated with
long-term mortality but was independently associated with a
higher incidence of HF-related admission. The impact of preexist-
ing AF on long-term HF-related admission seemed to be stronger
in patients with IHD, without valvular disease, and with preserved
EF, implying that unresolved clinical problems remain to be
clariﬁed.
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